AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19877047
Drug: dnaJP1 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dnaJP1 (25 mg daily for 6 months)
Trial: 19877047
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dnaJP1 and hydroxychloroquine (HCQ)
Trial: 8236004
Drug: Ketorolac 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.5% ophthalmic solution, four times a day for seven days
Trial: 17587217
Drug: Duloxetine 60-120
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60-120 mg once daily
Trial: 10555898
Drug: L-arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine supplementation (8 g daily for 28 days)
Trial: 8873688
Drug: Bumetanide (0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (0.005 to 0.10 mg/kg)
Trial: 1994758
Drug: Patient-controlled sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled sedation with midazolam (0.5 mg) and fentanyl (25 micrograms) administered via PCA infuser
Trial: 1994758
Drug: Sedation administered
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation administered by the anesthesiologist with 0.5‐1.0 mg intravenous midazolam and 25‐50 micrograms intravenous fentanyl
Trial: 6659643
Drug: Disopyramide (Di)
DrugBank: Disopyramide (DB00280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disopyramide (Di) 2.0 mg/kg intravenous
Trial: 6659643
Drug: Mexiletine (Me)
DrugBank: Mexiletine (DB00379)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mexiletine (Me) 3.0 mg/kg intravenous
Trial: 6659643
Drug: Propafenon (Pr)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenon (Pr) 1.5 mg/kg intravenous
Trial: 6659643
Drug: Disopyramide (Di)
DrugBank: Disopyramide (DB00280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disopyramide (Di) 4 X 200 mg/day oral
Trial: 6659643
Drug: Mexiletine (Me)
DrugBank: Mexiletine (DB00379)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mexiletine (Me) 4 X 200 mg/day oral
Trial: 6659643
Drug: Propafenon (Pr)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenon (Pr) 3 X 300 mg/day oral
Trial: 31014344
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered steroids (used as rescue medication)
Trial: 25425502
Drug: linagliptin 5mg
RxNorm normalized name: LINAGLIPTIN 5MG TAB
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linagliptin 5mg once daily
Trial: 25425502
Drug: glimepiride 1-4mg
RxNorm normalized name: glimepiride 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glimepiride 1-4mg once daily
Trial: 20156769
Drug: Co-trimoxazole (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (960 mg thrice weekly for 18 months)
Trial: 16537811
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in CCG 2891
Trial: 16537811
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in CCG 2961
Trial: 9870976
Drug: Morphine conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine conditioning with expectation cues
Trial: 9870976
Drug: Morphine conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine conditioning alone
Trial: 8876546
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS), 200 micrograms once daily
Trial: 8876546
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aqueous nasal spray (BDP), 168 micrograms twice daily
Trial: 6648357
Drug: Metoprolol, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol, administered twice daily over a period of 1 week
Trial: 6648357
Drug: Propranolol, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, administered for 1 week
Trial: 6648357
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication for 1 week
Trial: 31040253
Drug: Adjuvant zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adjuvant zoledronic acid (4 mg) intravenously at 1, 2, 3, 6, 9, and 12 months after surgery
Trial: 27488378
Drug: Tobramycin-impregnated bone
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin-impregnated bone cement (1 g/40 g)
Trial: 27488378
Drug: Intravenous tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous tobramycin (control group)
Trial: 22036088
Drug: Doxorubicin 75
RxNorm normalized name: DOXOrubicin 75 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg/m² and cisplatin 100 mg/m² (6 cycles)
Trial: 22036088
Drug: Grades 3-4
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Grades 3-4 oral mucositis
Trial: 17092664
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy for 3 months followed by 3 months of continuous estrogen and progesterone combined therapy
Trial: 17092664
Drug: Continuous estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous estrogen and progesterone therapy for 3 months
Trial: 17092664
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (estrogen and progesterone)
Trial: 16187913
Drug: TSH levels
RxNorm normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TSH levels below 0.3 mU/L
Trial: 16187913
Drug: Normal TSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal TSH levels (0.3-3.0 mU/L)
Trial: 16187913
Drug: TSH levels
RxNorm normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TSH levels above 3 mU/L
Trial: 16187913
Drug: TRAb levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRAb levels in relapse group (11.1 IU/L ± 0.17)
Trial: 16187913
Drug: TRAb cutoff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRAb cutoff value of 1.5 IU/L
Trial: 16187913
Drug: TRAb cutoff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRAb cutoff level of 10 IU/L
Trial: 7787129
Drug: saline‐polyethylene glycol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline‐polyethylene glycol solution (SPG)
Trial: 2079572
Drug: 3 megaunits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 megaunits of recombinant interferon alfa‐2b (INTRON A, R Schering‐Plough, Essex Corporation) subcutaneously thrice weekly for 4 months
Trial: 28545195
Drug: Self-administered questionnaire
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaire assessing knowledge and screening compliance
Trial: 25714882
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (3 g/daily)
Trial: 23949026
Drug: Premotor Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premotor Therapy
Trial: 23949026
Drug: Motor Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor Therapy
Trial: 21570514
Drug: Lipid-lowering medications
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering medications (LL)
Trial: 16934438
Drug: Lactobacillus paracasei
RxNorm normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus paracasei A (100 g/day of fermented milk)
Trial: 8592284
Drug: Topical butamben
RxNorm normalized name: butamben Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical butamben picrate
Trial: 40709
Drug: Ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (1 mg single dose)
Trial: 31657646
Drug: Withdrawal from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal from methylphenidate treatment
Trial: 29357480
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant human EPO (5,000 IU) over 4 weeks (n = 12)
Trial: 29357480
Drug: High-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose recombinant human EPO (500 IU·kg body wt‐1·day‐1 for three consecutive days) (n = 12)
Trial: 22994682
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both drugs (NAC and ascorbic acid)
Trial: 20605202
Drug: rosiglitazone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (2 mg) and metformin (500 mg) twice daily
Trial: 20605202
Drug: rosiglitazone and
RxNorm normalized name: Rosiglitazone and Glimepiride Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone and metformin
Trial: 16962381
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with antiretroviral therapy
Trial: 16962381
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (no early treatment)
Trial: 12866252
Drug: Fluoxetine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (n = 54)
Trial: 8043704
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate treatment
Trial: 31288233
Drug: Ustekinumab intravenous
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab intravenous infusion followed by subcutaneous maintenance dose of 90 mg every 8 weeks
Trial: 24479722
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of 20 mg methylprednisolone
Trial: 24479722
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid eye drops (dexamethasone 1 mg/ml)
Trial: 7662247
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitors (quinapril or captopril); duration: 6 months
Trial: 7662247
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitors (quinapril or captopril)
Trial: 29288055
Drug: Atorvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin + Ticagrelor
Trial: 27212277
Drug: Acyclovir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (800 mg five times daily for one week)
Trial: 23558303
Drug: High fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fluid management (8 mL/[kg · h])
Trial: 23558303
Drug: Low fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fluid management (2 mL/[kg · h])
Trial: 20854384
Drug: Cinnamon (2g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon (2g daily for 12 weeks)
Trial: 19114297
Drug: Buccal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Buccal midazolam (0.2mg/kg)
Trial: 19114297
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (0.3mg/kg)
Trial: 16244023
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg dolasetron IV
Trial: 10825320
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg dolasetron IV
Trial: 16244023
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ondansetron IV
Trial: 10825320
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg ondansetron IV
Trial: 3716654
Drug: Discontinued group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued group therapy
Trial: 3716654
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy (completed treatment)
Trial: 3716654
Drug: Standard psychoanalytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard psychoanalytic therapy
Trial: 3716654
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (discontinued group therapy)
Trial: 16382125
Drug: Overall therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall therapy
Trial: 30646650
Drug: Nursing intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nursing intervention in addition to routine treatment and respiratory function exercise
Trial: 30646650
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment and respiratory function exercise
Trial: 27698630
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory medication plus instructions on daily home stretching (control group)
Trial: 10367222
Drug: Nitroglycerin patch
RxNorm normalized name: Nitroglycerin Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patch (10 mg/24 h) administered four hours before tests in the acute phase.
Trial: 10367222
Drug: Nitroglycerin patch
RxNorm normalized name: Nitroglycerin Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patch (10 mg/24 h) administered continuously for 25 days in the chronic phase.
Trial: 10367222
Drug: ECG-dipyridamole test
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ECG-dipyridamole test after chronic therapy (Dip 2).
Trial: 7738625
Drug: Chemotherapy regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimens based on platinum derivatives
Trial: 1799916
Drug: Brodimoprim 200
RxNorm normalized name: brodimoprim 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodimoprim 200 mg once daily for 7-10 days
Trial: 1799916
Drug: Amoxicillin 750
RxNorm normalized name: amoxicillin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 750 mg thrice daily for 7-10 days
Trial: 7471129
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg clotrimazole vaginal tablet daily for seven days (group I)
Trial: 7471129
Drug: Two 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 100 mg clotrimazole vaginal tablets daily for three days (group II)
Trial: 31789307
Drug: Tri-modality therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-modality therapy
Trial: 28630863
Drug: Melatonin at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin at a dose of 2×5 mg with atorvastatin or rosuvastatin at a standardized daily dose of 20 mg
Trial: 28630863
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with atorvastatin or rosuvastatin at a standardized daily dose of 20 mg
Trial: 24142869
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) 200, 400, and 600 mg daily oral dose
Trial: 15283929
Drug: Soy germ
RxNorm normalized name: soy germ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy germ isoflavones (60 mg per day, capsules)
Trial: 11352236
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with step‐down prednisolone, methotrexate, and sulfasalazine
Trial: 9315415
Drug: Norplant implants
RxNorm normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norplant implants
Trial: 3328343
Drug: Permethrin-treated bed
RxNorm normalized name: Permethrin
DrugBank: Permethrin (DB04930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Permethrin-treated bed nets (0.5 g/m2)
Trial: 12153372
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and alternative medicine (CAM) use
Trial: 21062645
Drug: Moderate-intensity treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity treatment (primary care provider counseling plus additional counseling by an auxiliary staff member)
Trial: 21062645
Drug: Low-intensity control
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity control treatment (primary care provider counseling only)
Trial: 19054832
Drug: Topical anaesthetic
RxNorm normalized name: Topical anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic eye-drops only
Trial: 14978663
Drug: High-dose D-penicillamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose D-penicillamine (822 mg daily)
Trial: 14978663
Drug: Low-dose D-penicillamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose D-penicillamine (120 mg every other day)
Trial: 12202467
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg or more)
Trial: 7977218
Drug: Outpatient day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient day treatment program (28-day duration)
Trial: 2513172
Drug: Hypercaloric nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypercaloric nutrition (32 +/- 3.8 kcal/kg/d and 1.23 g/kg/d of protein)
Trial: 31943807
Drug: Family-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused therapy (FFT)
Trial: 19672568
Drug: EpiCor (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EpiCor (500 mg of a dried, modified Saccharomyces cerevisiae oral fermentation product)
Trial: 7803885
Drug: Prophylactic agents
RxNorm normalized name: Caries prophylactic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic agents (general)
Trial: 4311189
Drug: Corticotrophin gel
RxNorm normalized name: corticotropin Injectable Solution [ACTH Gel]
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticotrophin gel
Trial: 16442045
Drug: Laser lipolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser lipolysis followed by biweekly treatments with the Tri-active system
Trial: 11777511
Drug: Dexamethasone 16
RxNorm normalized name: dexamethasone 16 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 16 mg
Trial: 12538199
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (3.5-5 mg) plus ketamine (20/30 mg)
Trial: 12538199
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (3.5-5 mg)
Trial: 10396749
Drug: Type A
RxNorm normalized name: HLA type A IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type A botulinum toxin (AGN 191622) - 1 unit (group L)
Trial: 2405653
Drug: Intraperitoneal (IP)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (IP) cephalothin (250 mg/L) and tobramycin (8 mg/L)
Trial: 2405653
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin (400 mg loading followed by 300 mg daily)
Trial: 2405653
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ofloxacin (400 mg followed by 300 mg daily) and rifampicin (300 mg daily)
Trial: 6252744
Drug: FK 33-824
RxNorm normalized name: FK-960
DrugBank: FK-960 (DB06465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK 33-824 (0.5 mg im)
Trial: 6252744
Drug: Naloxone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (4 mg iv)
Trial: 31227978
Drug: Capsule debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule debridement during CIED replacement
Trial: 31227978
Drug: No capsule
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No capsule debridement during CIED replacement
Trial: 24117002
Drug: Iodine supplementation
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine supplementation (150 μg of potassium iodide daily) - Group A